In clinical work, PPARγ agonist glitazone—the derivative of thiazolidinediones—could improve insulin resistance by indirectly increasing insulin-stimulated glucose uptake in adipocytes, skeletal muscle cells, and hepatocytes and inhibiting proinflammation cytokines produced from mononuclear macrophages [22]. The gene discussed is PPARG; the disease is Insulin resistance.